# A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

> **NCT03492281** · PHASE3 · COMPLETED · sponsor: **Urovant Sciences GmbH** · enrollment: 1530 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** vibegron
- **DRUG:** Vibegron placebo
- **DRUG:** Tolterodine Tartrate ER
- **DRUG:** Tolterodine placebo

## Key facts

- **NCT ID:** NCT03492281
- **Lead sponsor:** Urovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2019-01-10
- **Final completion:** 2019-02-04
- **Target enrollment:** 1530 (ACTUAL)
- **Last updated:** 2021-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492281, "A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03492281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*